Cat.#: BBM-C-130
| Source | Brain |
| Disease | Normal |
| Species | Bovine |
| Cell Type | Endothelial |
| Description | Bovine Brain Microvascular Endothelial Cells (BBMVEC) from Ace Therapeutics are isolated from microvessels of the bovine brain. The cells are cryopreserved at the second passage. |
| Applications | The Bovine Brain Microvascular Endothelial Cells (BBMVEC), a model for studying the blood-brain barrier (BBB), allows researchers to investigate the transport of drugs across the blood-brain barrier, examine brain endothelial cell tight junctions, and explore the basic biology of brain microvascular endothelial cells more effectively. The endothelial cells in this system exhibit tight junctions (positive for proteins ZO-1 and Claudin-1) and have transport characteristics similar to those found in the blood-brain barrier (such as P-glycoprotein function). Therefore, it can be used in initial ADME-Tox screening assays to determine if test compounds are likely to penetrate the blood-brain barrier. |
| Quality Control | Bovine Brain Microvascular Endothelial Cells (BBMVEC) test negative for bacteria, yeast, fungi, and mycoplasma. |
| Shipping and Storage | Ace Therapeutics ships frozen cells using dry ice. Upon receiving the frozen cells, immediately move them into liquid nitrogen (-180 °C) for storage. Note: Never can cells be kept at -20 °C, and repeated freezing and thawing of cells is not recommended. |
| Cat.# | Name | Description | Price |
|---|---|---|---|
| BBM-C-128 | BALB/c Mouse Brain Microvascular Endothelial Cells |
BALB/c Mouse Brain Microvascular Endothelial Cells from Ace Therapeutics are isolated from the brain tissue of pathogen-free laboratory mice. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-139 | CD1 Mouse Astrocytes |
CD1 Mouse Astrocytes from Ace Therapeutics are isolated from postnatal day 2 mouse brains. MA is characterized by immunofluorescence with antibodies specific to GFAP. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-129 | Rat Brain Microvascular Endothelial Cells |
Rat Primary Brain Microvascular Endothelial Cells (RPBECs) from Ace Therapeutics are isolated from the brain tissue of 1-day-old neonatal Sprague-Dawley rats. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-144 | Rat Astrocytes |
Rat Astrocytes (RA) from Ace Therapeutics are isolated from postnatal day 2 rat brains and are cryopreserved as primary cultures. Each vial contains at least 0.5×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-143 | Mouse Astrocytes-cerebellar from CD1 |
Mouse Astrocytes-cerebellar from CD1 from Ace Therapeutics are isolated from a pathogen-free mouse cerebellar and are cryopreserved as primary cultures. Each vial contains at least 0.5×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-147 | Rat Astrocytes-midbrain |
Rat astrocytes-midbrain (RA-mb) from Ace Therapeutics are isolated from CD® IGS rat midbrain and are cryopreserved at P0. RA-mb are characterized by immunofluorescence with antibodies specific to GFAP. Each vial contains at least 0.5×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-146 | Sprague-Dawly (SD) Rat Astrocytes |
Characterization: 1. Cell Activity;
– Recovery Viability ≥ 80%.
2. Cell Purity;
– GFAP-positive cells ≥ 70%.
– β-tubulin III- or doublecortin- (Dcx-) positive cells ≤ 10%.
– GalC-positive cells ≤ 10%.
|
inquiry |
| BBM-C-142 | Mouse Astrocytes-brain stem from CD1 |
Mouse Astrocytes-brain stem from CD1 (MA-bs) are isolated from embryonic day 15 mouse brain stem. MA-bs are cryopreserved as primary cultures and delivered frozen.
|
inquiry |
| BBM-C-125 | CD1 Mouse Brain Microvascular Endothelial Cells |
CD1 Mouse Brain Microvascular Endothelial Cells from Ace Therapeutics are isolated from brain tissue of pathogen-free laboratory mice. Each vial contains at least 1×10^6 cells per ml and is delivered frozen.
|
inquiry |
| BBM-C-145 | Wistar Rat Astrocytes |
Characterization: 1. Cell Activity;
– Recovery Viability ≥ 80%.
2. Cell Purity;
– GFAP-positive cells ≥ 70%.
– β-tubulin III- or doublecortin- (Dcx-) positive cells ≤ 10%.
– GalC-positive cells ≤ 10%.
|
inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.